Faculty, Staff and Student Publications
Publication Date
9-2-2022
Journal
Cancers
DOI
10.3390/cancers14174310
PMID
36077845
PMCID
PMC9454976
PubMedCentral® Posted Date
9-2-2022
PubMedCentral® Full Text Version
Post-print
Abstract
Despite aggressive combination chemotherapy and surgery, outcomes for patients with osteosarcoma have remained stagnant for more than 25 years, and numerous clinical trials have identified no new therapies. p53 deletion or mutation is found in more than 80% of osteosarcoma tumors. In p53-deficient cancers with structurally altered p63 and p73, interfering with tumor cell metabolism using Pramlintide (an FDA-approved drug for type 2 diabetes) results in tumor regression. Pramlintide response is mediated through upregulation of islet amyloid polypeptide (IAPP). Here, we showed that osteosarcoma cells have altered p63, p73, and p53, and decreased IAPP expression but have the two main IAPP receptors, CalcR and RAMP3, which inhibit glycolysis and induce apoptosis. We showed that in osteosarcoma cells with high- or mid-range glycolytic activity, Pramlintide decreased cell glycolysis, resulting in decreased proliferation and increased apoptosis in vitro. In contrast, Pramlintide had no effect in osteosarcoma cells with low glycolytic activity. Using a subcutaneous osteosarcoma mouse model, we showed that intratumoral injection of Pramlintide-induced tumor regression. Tumor sections showed increased apoptosis and a decrease in Ki-67 and HIF-1α. These data suggest that in osteosarcoma cells with altered p53, p63, and p73 and a high glycolytic function, Pramlintide therapy can modulate metabolic programming and inhibit tumor growth.
Keywords
osteosarcoma, pramlintide, IAPP, p53, p63, p73, glycolytic metabolism
Published Open-Access
yes
Recommended Citation
Yang, Yuanzheng; Peng, Zhanglong; Flores, Elsa R; et al., "Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming" (2022). Faculty, Staff and Student Publications. 4593.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/4593
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons